Division of Endocrinology, Metabolism and Lipid Research, Department of Neurosurgery, Washington University School of MedicineSt. Louis, Missouri, United States
Disclosure information not submitted.
MON-036 - Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension
Monday, June 15, 20269:00 AM - 2:00 PM CT
MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial
.jpg)
.jpg)